Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi’s Sakigake-Designated Flu Med Filed in Japan
Shionogi filed a new drug application for its anti-flu drug S-033188 in Japan on October 25, making the drug the second pharmaceutical product granted the sakigake fast-track designation to reach regulatory submission - only after Nobelpharma’s topical sirolimus. S-033188, which…
To read the full story
Related Article
- Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
- Xofluza to Join NHI Price List March 14 as Key Panel Gives Expedited OK
March 7, 2018
- Shionogi’s Sakigake-Designated Flu Med Up for MHLW Panel Review on Feb. 2, Early Listing Possible?
January 23, 2018
- Shionogi to File Sakigake-Designated Flu Drug by Year-End Based on PIII Results
September 15, 2017
- Positive Top-Line Data Out for Shionogi’s Sakigake-Designated Flu Med
July 25, 2017
- Shionogi’s Sakigake-Designated Flu Drug Delivers Add’l Favorable PII Data
December 5, 2016
- Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
August 30, 2016
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
- Shionogi Closes Acquisition of Tanabe’s Edaravone Business
April 3, 2026
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…